These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23992630)

  • 1. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
    Chen JH; Yu H; Lin M; Mehta RS; Su MY
    Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
    Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
    Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
    Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
    Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.
    King V; Gu Y; Kaplan JB; Brooks JD; Pike MC; Morris EA
    Eur Radiol; 2012 Dec; 22(12):2641-7. PubMed ID: 22752463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
    You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
    Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
    Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
    Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Chen JH; Yu HJ; Hsu C; Mehta RS; Carpenter PM; Su MY
    Transl Oncol; 2015 Jun; 8(3):204-9. PubMed ID: 26055178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
    Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
    Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
    King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
    Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
    Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
    Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
    Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
    Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
    Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
    Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
    Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C
    Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.
    Price ER; Brooks JD; Watson EJ; Brennan SB; Comen EA; Morris EA
    Eur Radiol; 2014 Jan; 24(1):162-8. PubMed ID: 23982290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?
    Bermot C; Saint-Martin C; Malhaire C; Sebbag-Sfez D; Mouret-Fourme E; Carton M; Thibault FE
    Eur J Radiol; 2018 Dec; 109():171-177. PubMed ID: 30527300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI.
    La Forgia D; Vestito A; Lasciarrea M; Comes MC; Diotaiuti S; Giotta F; Latorre A; Lorusso V; Massafra R; Palmiotti G; Rinaldi L; Signorile R; Gatta G; Fanizzi A
    J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33915842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
    Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
    J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.